Review of NICE Technology Appraisal Guidance No.315; Canagliflozin in combination therapy for treating type 2 diabetes
Proposal to move the existing guidance to the static list
As you may be aware the planned date for review of the above guidance was May 2017.
This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.
No new evidence has been identified that is likely to lead to a change in the existing recommendations.
Consequently we propose that TA315 should move to the ‘static list’ of technology appraisals.
Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
This page was last updated: